WFS1 rs10010131: Pharmacogenomics and Metabolic Response
The rs10010131 variant is a single-nucleotide polymorphism located within the WFS1 gene. Research suggests this variant may influence how individuals respond to certain diabetes medications, specifically regarding body weight reduction and renal markers.
What each genotype means
Enhanced weight loss response
Research indicates that carriers of the A allele may experience more pronounced body weight reduction when treated with SGLT2 inhibitors like dapagliflozin. This genotype has also been associated with altered renal responses, such as elevated serum urea levels, during SGLT2 inhibitor therapy. Please discuss these potential medication-response patterns with your clinician or pharmacist to determine if they are relevant to your treatment plan.
The A allele is common, though its frequency varies significantly across different global populations.
Intermediate weight loss response
Individuals with this genotype carry one copy of the A allele, which has been linked to a greater reduction in body weight during treatment with SGLT2 inhibitors compared to those without the allele. Studies also suggest a potential association with changes in kidney-related markers like serum urea when using these medications. You should consult your healthcare provider or pharmacist to discuss how your genetic profile might influence your response to specific diabetes therapies.
This heterozygous genotype is frequently observed in many populations, reflecting the common nature of both the A and G alleles.
Typical response profile
This genotype represents the absence of the A allele associated with enhanced weight loss in studies of SGLT2 inhibitor therapy. Research suggests that individuals with this genotype may not exhibit the same degree of weight reduction or the specific renal marker changes observed in A-allele carriers when taking these medications. Always consult with your clinician or pharmacist regarding your personal response to any prescribed diabetes medication.
The G allele is a major allele in many populations, making the GG genotype common across various ancestries.
Understanding the rs10010131 Variant
The rs10010131 variant is a common genetic change located within the WFS1 gene, which provides instructions for making a protein called wolframin. This protein is primarily found in the endoplasmic reticulum of cells, where it plays a critical role in maintaining cellular health, particularly in pancreatic beta cells that produce insulin. The rs10010131 SNP is situated in an intronic region of the gene. While it does not change the protein sequence directly, it is often studied as a marker for regulatory effects on gene expression. Because this variant is frequently inherited alongside other nearby genetic changes, it is often analyzed as part of a larger haplotype block. Scientists use this SNP to investigate how subtle variations in the WFS1 gene might contribute to differences in metabolic health and how the body processes specific pharmaceutical treatments.
The Role of the WFS1 Gene
The WFS1 gene is best known for its association with Wolfram syndrome, a rare condition caused by rare, high-impact mutations. However, common variants in the same gene, such as rs10010131, have been extensively studied for their influence on common metabolic conditions like type 2 diabetes. The wolframin protein is essential for regulating calcium levels within the cell and managing the unfolded protein response, a mechanism that helps cells cope with stress. When WFS1 expression is altered, it can affect the function of insulin-secreting cells. Research has indicated that certain alleles of rs10010131 are associated with differences in how the body secretes insulin in response to glucose and other stimuli. By studying these common variants, researchers aim to better understand the biological pathways that regulate blood sugar and how these pathways might be modulated by therapeutic interventions.
Pharmacogenomic Associations
Recent research has highlighted a potential pharmacogenetic role for rs10010131 in patients treated with SGLT2 inhibitors, such as dapagliflozin. Studies have observed that carriers of the A allele may experience a more pronounced reduction in body weight when treated with a combination of dapagliflozin and exenatide. Additionally, some evidence suggests that this allele may be linked to elevated serum urea levels in patients specifically undergoing SGLT2 inhibitor therapy, potentially reflecting a renal adaptive response. It is important to note that these findings are based on specific clinical cohorts and require further validation in larger, more diverse populations. The evidence for these associations is considered moderate, and the clinical significance of these metabolic and renal changes is still being explored. These observations underscore the complexity of drug response and the potential for genetic markers to eventually help tailor metabolic therapies.
What This Information Means for You
If you have information about your rs10010131 genotype, it is important to view it as a piece of scientific data rather than a medical diagnosis. Genetic associations with drug response are complex and influenced by many factors, including diet, lifestyle, and other medications. You should never use genetic information to start, stop, or change the dosage of any medication on your own. If you are currently taking SGLT2 inhibitors or other diabetes medications, discuss your treatment plan and any concerns about your response to therapy with your healthcare provider or a clinical pharmacist. They are the best equipped to interpret your clinical history alongside any genetic information you may have. Precision medicine is an evolving field, and while genetic markers like rs10010131 provide interesting insights into biological variability, they are currently just one part of a comprehensive approach to managing metabolic health.
How common is this variant?
The frequency of the rs10010131 alleles is variable across different global populations, with the G allele often identified as the major allele in many studied cohorts.
Frequently asked questions
Can I use my rs10010131 result to choose my diabetes medication?
No. Genetic markers are currently used for research purposes and are not standard tools for selecting diabetes medications. Always consult your doctor to determine the most appropriate treatment plan for your specific health needs.
Is rs10010131 a diagnostic test for diabetes?
No. This variant is a common genetic marker associated with metabolic traits and drug response, not a diagnostic test for type 2 diabetes. Diabetes is diagnosed through clinical blood tests like HbA1c and fasting glucose.
What should I do if I have the A allele?
The presence of the A allele does not require any specific action. It is a common genetic variation, and you should continue to follow the treatment plan prescribed by your healthcare provider.
Where can I find more information about WFS1?
You can find reliable information about the WFS1 gene and its functions on resources like MedlinePlus Genetics or the NCBI Gene database. These sites provide comprehensive, peer-reviewed summaries of gene functions and associated conditions.
Sources & further reading
Educational information only, last refreshed 11/2/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs10010131?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29